ExpreS2ion Biotechnologies Announces Further Data On The Covid-19

Michael Friis

Michael Friis

ExpreS2ion Biotechnologies together with their partner Bavarian Nordic today announced further data on the Covid-19 vaccine candidate, regarding the effect on the omicron variant.


The release is without any specific datapoint but states:  

“The new study data demonstrates a significant boost to the neutralizing antibodies against the Omicron variant in the majority of subjects with a fold increase in the same range as previously reported for the original Wuhan SARS-CoV2 variant”.

Relating to further process the release state Bavarian Nordic continues to plan for rapid initiation of a Phase III study

The market have been waiting for data on the omicron variant, but maybe more important this shows that the candidate could have a broad reach, and therefore also on new and future variants .

Regarding the market outlook which might be the other uincertanity in the market, both moderna and Pfizer gave an update this week, where they confirmed already given guidance in the start of the year.

In Moderna’s case they expect t sell more of this in second half, giving some hints that they expects waves in the later part of this year.

On the longer time horizon, the most interesting comments are probably doming from Fauci saying last week, that herd immunity is not possible, and stating new and better vaccines for the long run is needed.

HC Andersen Capital receives payment from ExpreS2ion Biotechnologies trough a Digital IR/Corporate Visibility agreement./Michael Friis, 05-05-2022, kl. 11:25